|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J Thorac Cardiovasc Surg 2009;137:929-933
© 2009 The American Association for Thoracic Surgery
Congenital Heart Disease |
a Department of Thoracic and Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
b Department of Echocardiography, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
c Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
Received for publication May 22, 2008; revisions received August 18, 2008; accepted for publication September 1, 2008. * Address for reprints: Qi An, MD, Department of Thoracic and Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China, 610041. (Email: anqi8890{at}163.com).
Objective: The conventional surgical repair and transcatheter closure of muscular ventricular septal defects are known to have undesirable limitations. This communication describes the short-term results of perventricular device closure of muscular ventricular septal defects with the heart beating in 8 children with 15 muscular ventricular septal defects, with or without other congenital malformations.
Methods: A subxiphoid minimally invasive incision was used in 3 children with isolated muscular ventricular septal defects whereas standard full median sternotomies were used in the other 5 children who required subsequent correction of coexisting malformations. Under the continuous guidance of transesophageal echocardiography, the free wall of the right ventricle was punctured, and a guidewire was introduced into the left ventricle through the defect. A delivery sheath was advanced over the wire and through the defect into the left ventricle. The device was released.
Results: A total of 14 muscular ventricular septal defects were successfully closed perventricularly without cardiopulmonary bypass. There was no mortality perioperatively or during the entire follow-up period. At 6-month follow-up, there was no detectable residual shunt, arrhythmia, or new mitral or tricuspid insufficiency. Other than 5 children with the coexisting malformations, none of the other children required any blood or blood products. The average hospital stay was 7.9 ± 2.2 days (range, 5–11 days).
Conclusion: Perventricular device closure of muscular ventricular septal defects with or without coexisting congenital malformations appeared to be safe and efficacious. The outcomes of short-term follow-up are acceptable.
This article has been cited by other articles:
![]() |
Q. Xing, Q. Wu, S. Pan, Y. Ren, and H. Wan Transthoracic device closure of ventricular septal defects without cardiopulmonary bypass: experience in infants weighting less than 8 kg Eur J Cardiothorac Surg, September 1, 2011; 40(3): 591 - 597. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Feltes, E. Bacha, R. H. Beekman III, J. P. Cheatham, J. A. Feinstein, A. S. Gomes, Z. M. Hijazi, F. F. Ing, M. de Moor, W. R. Morrow, et al. Indications for Cardiac Catheterization and Intervention in Pediatric Cardiac Disease: A Scientific Statement From the American Heart Association Circulation, June 7, 2011; 123(22): 2607 - 2652. [Full Text] [PDF] |
||||
![]() |
Q. Xing, S. Pan, Q. An, Z. Zhang, J. Li, F. Li, Q. Wu, and Z. Zhuang Minimally invasive perventricular device closure of perimembranous ventricular septal defect without cardiopulmonary bypass: Multicenter experience and mid-term follow-up J. Thorac. Cardiovasc. Surg., June 1, 2010; 139(6): 1409 - 1415. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |